Literature DB >> 23597374

Missed opportunities for hepatitis C testing in opioid treatment programs.

Jemima A Frimpong1.   

Abstract

HCV has surpassed HIV as a cause of death in the United States and is particularly prevalent among injection drug users. I examined the availability of on-site HCV testing in a nationally representative sample of opioid treatment programs. Nearly 68% of these programs had the staff required for HCV testing, but only 34% offered on-site testing. Availability of on-site testing increased only slightly with the proportion of injection drug users among clients. The limited HCV testing services in opioid treatment programs is a key challenge to reducing HCV in the US population.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23597374      PMCID： PMC3670662          DOI： 10.2105/AJPH.2012.301129

Source DB:  PubMed          Journal:  Am J Public Health        ISSN： 0090-0036            Impact factor:   9.308


  20 in total

1.  Survey of hepatitis B and C in addiction treatment unit.

Authors:  V P Dhopesh; K R Taylor; W M Burke
Journal:  Am J Drug Alcohol Abuse       Date:  2000-11       Impact factor: 3.829

2.  HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005.

Authors:  Harold A Pollack; Thomas D'Aunno
Journal:  J Subst Abuse Treat       Date:  2010-02-19

3.  Successful integration of hepatitis C evaluation and treatment services with methadone maintenance.

Authors:  Kenneth A Harris; Julia H Arnsten; Alain H Litwin
Journal:  J Addict Med       Date:  2010-03       Impact factor: 3.702

4.  Overcoming barriers to HIV testing: preferences for new strategies among clients of a needle exchange, a sexually transmitted disease clinic, and sex venues for men who have sex with men.

Authors:  Freya Spielberg; Bernard M Branson; Gary M Goldbaum; David Lockhart; Ann Kurth; Connie L Celum; Anthony Rossini; Cathy W Critchlow; Robert W Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2003-03-01       Impact factor: 3.731

5.  Provision of on-site medical care to patients with hepatitis C in drug treatment units.

Authors:  Zdravko P Vassilev; Shiela M Strauss; Janetta M Astone; Peter D Friedmann; Don C Des Jarlais
Journal:  J Health Care Poor Underserved       Date:  2004-11

6.  An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units.

Authors:  T D'Aunno; T E Vaughn; P McElroy
Journal:  J Health Soc Behav       Date:  1999-06

7.  The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; John W Ward; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

8.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Authors:  Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

9.  Changing trends in hepatitis C-related mortality in the United States, 1995-2004.

Authors:  Matthew Wise; Stephanie Bialek; Lyn Finelli; Beth P Bell; Frank Sorvillo
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

10.  Changes in methadone treatment practices: results from a national panel study, 1988-2000.

Authors:  Thomas D'Aunno; Harold A Pollack
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272
View more
  15 in total

1.  Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance.

Authors:  Rachel E Gicquelais; Betsy Foxman; Joseph Coyle; Marisa C Eisenberg
Journal:  Epidemics       Date:  2019-02-28       Impact factor: 4.396

2.  Missed opportunities for hepatitis C testing and other opportunistic health care.

Authors:  M Mofizul Islam
Journal:  Am J Public Health       Date:  2013-10-17       Impact factor: 9.308

3.  Increasing Prevalence of Chronic Hepatitis C Virus Infection in a Southern Academic Obstetrical Clinic.

Authors:  Gweneth B Lazenby; Cody Orr; Constance Guille; Eric G Meissner
Journal:  South Med J       Date:  2019-06       Impact factor: 0.954

4.  Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.

Authors:  Jemima A Frimpong; Thomas D'Aunno; Lan Jiang
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

5.  An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.

Authors:  David C Perlman; Ashly E Jordan; Anneli Uuskula; Duong Thi Huong; Carmen L Masson; Bruce R Schackman; Don C Des Jarlais
Journal:  Int J Drug Policy       Date:  2015-04-27

6.  Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients.

Authors:  Diana Hernández; Daniel J Feaster; Lauren Gooden; Antoine Douaihy; Raul Mandler; Sarah J Erickson; Tiffany Kyle; Louise Haynes; Robert Schwartz; Moupali Das; Lisa Metsch
Journal:  AIDS Behav       Date:  2016-01

7.  A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.

Authors:  Sean J Haley; Mary Jeanne Kreek
Journal:  Am J Public Health       Date:  2015-01-20       Impact factor: 9.308

8.  Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.

Authors:  Ashly E Jordan; Charles M Cleland; Bruce R Schackman; Katarzyna Wyka; David C Perlman; Denis Nash
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

9.  Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings.

Authors:  Sugy Choi; Shannon Healy; Liudmila Shapoval; Sarah Forthal; Charles J Neighbors
Journal:  Subst Use Misuse       Date:  2020-12-21       Impact factor: 2.164

10.  Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.

Authors:  Bruce R Schackman; Jared A Leff; Devra M Barter; Madeline A DiLorenzo; Daniel J Feaster; Lisa R Metsch; Kenneth A Freedberg; Benjamin P Linas
Journal:  Addiction       Date:  2015-01       Impact factor: 7.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.